These studies implicate a critical inhibitory role of FoxO3 in IPF fibrogenesis and proof of concept for therapeutic reactivation of FoxO3 as an effective therapeutic strategy for pulmonary fibrosis. This evidence concerns the gene FOXO3 and idiopathic pulmonary fibrosis.